Showing 3581-3590 of 7016 results for "".
A Doctor's Stress Relief Checklist for the Holidays
https://reachmd.com/programs/everyday-family-medicine/a-doctors-stress-relief-checklist-holidays/8460/The holidays can be a stressful time for everyone, and healthcare professionals are no exception.Cracking the Code of Obstruction: Unmet Needs in oHCM
https://reachmd.com/programs/cme/cracking-the-code-of-obstruction-unmet-needs-in-ohcm/54837/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
https://reachmd.com/programs/cme/innovations-in-oncology-learning-center-from-guidelines-to-practice-melanoma/33212/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.At the Lid Line: Unmasking Demodex Across the OSD Spectrum
https://reachmd.com/programs/cme/at-the-lid-line-unmasking-demodex-across-the-osd-spectrum/54261/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
https://reachmd.com/programs/cme/optimizing-raasimra-therapy-in-patients-with-heart-failure-ckd-and-hyperkalemia-a-microlearning-curriculum-approach/26750/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Safety First: Navigating CELMoD-Associated Toxicities
https://reachmd.com/programs/cme/safety-first-navigating-celmod-associated-toxicities/36571/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityTriple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
https://reachmd.com/programs/cme/Triple-Threat-Key-Data-on-Simultaneous-Estrogen-CDK4-6-and-PI3K-Inhibition-in-mBC/37335/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
https://reachmd.com/programs/cme/navigating-the-therapeutic-landscape-of-platinum-resistant-ovarian-cancer/37667/CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian CancerFUE vs FUT: Key Considerations for Patient Selection
https://reachmd.com/programs/dermconsult/fue-fut-patient-selection-considerations/49026/Understanding the differences between follicular unit extraction (FUE) and follicular unit transplantation (FUT) is essential for selecting the most appropriate approach for each patient. Dr. Marc Avram shares how harvesting methods, scarring patterns, and other patient-specific consideratio